Finance

Lists
Why is AKUMS down 2,51%?
Dive Deeper
AKUMS:NSE
Akums Drugs and Pharmaceuticals Ltd
731,00 ₹
-2,51%
(-18,80) 1D
16 հոկ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AKUMS...
Open
749,80 ₹
High
752,80 ₹
Low
728,70 ₹
Mkt. cap
111,92 մլրդ
Avg. vol.
272,03 հզր
Volume
150,74 հզր
Dividend
0,14%
Quarterly dividend
0,25 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
38,38
52-wk high
838,80 ₹
52-wk low
409,30 ₹
EPS
19,05 ₹
No. of employees
7 հզր
Open
749,80 ₹
High
752,80 ₹
Low
728,70 ₹
Mkt. cap
111,92 մլրդ
Avg. vol.
272,03 հզր
Volume
150,74 հզր
Dividend
0,14%
Quarterly dividend
0,25 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
38,38
52-wk high
838,80 ₹
52-wk low
409,30 ₹
EPS
19,05 ₹
No. of employees
7 հզր
News stories
From web sources and news partners
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7,34 հզր
Founded2004
Headquarters-
Sector-
Websiteakums.in
Last report
10 օգս, 2026 թ.
Fiscal period
Q1 2027
6,53 ₹ / 6,10 ₹
+7,05%beat
Revenue / Est. (INR)
11,67 մլրդ / 11,65 մլրդ
+0,14%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
10,18 մլրդ
11,60 մլրդ
11,60 մլրդ
11,67 մլրդ
Cost of goods sold
5,93 մլրդ
6,79 մլրդ
7,37 մլրդ
6,45 մլրդ
Cost of revenue
5,93 մլրդ
6,79 մլրդ
7,37 մլրդ
6,45 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 մլրդ
1,89 մլրդ
2,37 մլրդ
2,01 մլրդ
Operating expense
3,68 մլրդ
3,74 մլրդ
3,09 մլրդ
3,88 մլրդ
Total operating expenses
9,61 մլրդ
10,52 մլրդ
10,46 մլրդ
10,33 մլրդ
Operating income
566,12 մլն
1,07 մլրդ
1,14 մլրդ
1,34 մլրդ
Other non operating income
323,65 մլն
343,28 մլն
-942,12 մլն
303,80 մլն
EBT including unusual items
656,73 մլն
995,66 մլն
1,21 մլրդ
1,39 մլրդ
EBT excluding unusual items
656,73 մլն
1,18 մլրդ
1,19 մլրդ
1,39 մլրդ
Income tax expense
229,77 մլն
318,92 մլն
398,74 մլն
382,59 մլն
Effective tax rate
34,99%
32,03%
32,89%
27,48%
Other operating expenses
1,41 մլրդ
1,45 մլրդ
319,86 մլն
1,45 մլրդ
Net income
407,83 մլն
663,17 մլն
846,13 մլն
1,00 մլրդ
Net profit margin
4,01%
5,72%
7,29%
8,57%
Earnings per share
2,66
5,14
-
6,53
Interest and investment income
-
-
1,10 մլրդ
-
Interest expense
-233,04 մլն
-237,42 մլն
-184,41 մլն
-247,56 մլն
Net interest expenses
-233,04 մլն
-237,42 մլն
912,36 մլն
-247,56 մլն
Depreciation and amortization charges
378,64 մլն
396,49 մլն
401,18 մլն
410,65 մլն
EBITDA
940,04 մլն
1,42 մլրդ
1,49 մլրդ
1,69 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps